Juan Manuel Calleja-Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Juan Manuel Calleja-Castillo has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Barboza Elizondo
Neurosciences Department, Hospital Dr. Rafael A. Calderón Guardia, CCSS, San José, Costa Rica
2 shared publications A. Arauz
Nuclear Cardiology, Instituto Nacional de Cardiologı́a Ignacio Chávez; Stroke Clinic, Instituto Nacional de Neurologı́a y Neurocirugı́a, Mexico City, México
1 shared publicationA. Hernandez
Reproductive Health and Chronic Disease Division, National Public Health Institute, Mexico City, Mexico
1 shared publicationA. Leyva
Nuclear Cardiology, Instituto Nacional de Cardiologı́a Ignacio Chávez; Stroke Clinic, Instituto Nacional de Neurologı́a y Neurocirugı́a, Mexico City, México
1 shared publication- Abiel Homero Mascareñas-De Los Santos
Department of Pediatrics, Infectious Diseases Service, Universidad Autónoma de Nuevo León. Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Nuevo León, Mexico
1 shared publication - Adriana Guzman-Holst
GSK, London, UK
1 shared publication
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e047114
Stroke Burden Attributable to Risk Factors in the Americas, 1990 to 2021: A Temporal Trends Analysis From the GBD Study 2021
Background: Stroke burden varies across the Americas, yet data on modifiable risk factor contributions remain limited. Methods: Using GBD (Global Burden of Disease) study 2021 data, we analyzed stroke mortality and disability‐adjusted life‐year (DALY) rates attributable to 23 modifiable risk factors across 39 countries and territories in the Americas. Age‐standardized rates were compared by sex, stroke subtype, region, and Socio‐Demographic Index; age‐specific estimates used 5‐year groups (25–95+ years). Trends were assessed using average annual percentage change (AAPC) from Joinpoint regression. Results: In 2021, 78.8% (95% uncertainty interval, 70.1%–85.9%) of stroke deaths and 76.9% (68.2%–83.6%) of DALYs were attributable to the 23 risk factors combined. High systolic blood pressure was the leading contributor, accounting for 20.87 attributable deaths (95% uncertainty interval, 15.17–25.80) and 453.30 DALYs (333.16–556.41) per 100 000, representing 54.8% of deaths and 52.2% of DALYs. From 1990 to 2021, the largest reductions occurred for household air pollution from solid fuels (deaths AAPC, −5.09% [95% CI, −5.17 to −5.02]; DALYs AAPC, −4.92% [−4.98 to −4.86]) and secondhand smoke (deaths AAPC, −3.45% [−3.49 to −3.41]). Reductions were minimal for high body mass index (deaths AAPC, −0.54% [−0.59 to −0.49]; DALYs AAPC, −0.42% [−0.46 to −0.37]), high fasting plasma glucose (deaths AAPC, −1.10% [−1.14 to −1.06]), and dietary risks; high body mass index burden increased in the Caribbean, notably in Haiti and the Dominican Republic. Stroke deaths attributable to high temperature increased >3.5% annually (AAPC) in Panama, Jamaica, and the Dominican Republic. High systolic blood pressure burden remained highly unequal, with age‐standardized death rates of 10.42 per 100 000 in high–Socio‐Demographic Index versus 109.33 in low–Socio‐Demographic Index countries. Conclusions: Stroke burden attributable to modifiable risk factors declined overall, but marked disparities persisted. High systolic blood pressure remained dominant, whereas stalled or increasing burden from obesity, metabolic, and dietary risks highlights the need for equity‐focused prevention across the Americas.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e047114
Stroke Burden Attributable to Risk Factors in the Americas, 1990 to 2021: A Temporal Trends Analysis From the GBD Study 2021
Background: Stroke burden varies across the Americas, yet data on modifiable risk factor contributions remain limited. Methods: Using GBD (Global Burden of Disease) study 2021 data, we analyzed stroke mortality and disability‐adjusted life‐year (DALY) rates attributable to 23 modifiable risk factors across 39 countries and territories in the Americas. Age‐standardized rates were compared by sex, stroke subtype, region, and Socio‐Demographic Index; age‐specific estimates used 5‐year groups (25–95+ years). Trends were assessed using average annual percentage change (AAPC) from Joinpoint regression. Results: In 2021, 78.8% (95% uncertainty interval, 70.1%–85.9%) of stroke deaths and 76.9% (68.2%–83.6%) of DALYs were attributable to the 23 risk factors combined. High systolic blood pressure was the leading contributor, accounting for 20.87 attributable deaths (95% uncertainty interval, 15.17–25.80) and 453.30 DALYs (333.16–556.41) per 100 000, representing 54.8% of deaths and 52.2% of DALYs. From 1990 to 2021, the largest reductions occurred for household air pollution from solid fuels (deaths AAPC, −5.09% [95% CI, −5.17 to −5.02]; DALYs AAPC, −4.92% [−4.98 to −4.86]) and secondhand smoke (deaths AAPC, −3.45% [−3.49 to −3.41]). Reductions were minimal for high body mass index (deaths AAPC, −0.54% [−0.59 to −0.49]; DALYs AAPC, −0.42% [−0.46 to −0.37]), high fasting plasma glucose (deaths AAPC, −1.10% [−1.14 to −1.06]), and dietary risks; high body mass index burden increased in the Caribbean, notably in Haiti and the Dominican Republic. Stroke deaths attributable to high temperature increased >3.5% annually (AAPC) in Panama, Jamaica, and the Dominican Republic. High systolic blood pressure burden remained highly unequal, with age‐standardized death rates of 10.42 per 100 000 in high–Socio‐Demographic Index versus 109.33 in low–Socio‐Demographic Index countries. Conclusions: Stroke burden attributable to modifiable risk factors declined overall, but marked disparities persisted. High systolic blood pressure remained dominant, whereas stalled or increasing burden from obesity, metabolic, and dietary risks highlights the need for equity‐focused prevention across the Americas.
- Open Access
Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.
Open AccessChallenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.
- 1 January 2023
- Published by Turkish Neurosurgical Society in Turkish Neurosurgery
- Vol. 34 (4) , 695-700
Effect of size and location of unruptured intracranial aneurysms on self-reported headache
AIM: To describe the relationship between aneurysm size and location with the prevalence of headache at diagnosis and three- and six-month follow-up in a sample of patients with UIA. MATERIAL and METHODS: In this cohort study, patients were diagnosed with UIAs by digital subtraction angiography (DSA). Follow-up visits occurred three and six months after the diagnosis. Headache presence was registered, and headache was further classified by phenotypes. After DSA, the recorded variables were aneurysm number, morphology, location, and size (diameter [W], neck [N], and dome-neck distance [H]). The aspect ratio (H/N) and the dome/neck ratio (W/N) were calculated. The outcome of this study was the self-reported headache status at follow-up. RESULTS: Data from 42 patients and 46 aneurysms were available; 81.0% of patients were women, with a mean age of 57.4 +/- 14.3 years. Headache was reported by 61.9% of the patients. The pain phenotype was tension-type in 38.1%, migraine in 11.9%, neuralgia in 2.4%, and unclassifiable in 9.5%. The median (min-max) measurements were W=5.05 (0.89-22.9); N=3.02 (0.52-17.9); H=5.08 (0.92-23.0); aspect ratio 1.59 (0.68-17.69) and W/N ratio 1.65 (0.62-16.92). Thirty-three patients (37 aneurysms) received treatment, 47.8% by surgical clipping and 32.6% by endovascular occlusion. In the treated patients, headaches had persisted in 14.3% until the first visit and in 9.5% until the second visit. There were no differences in any registered variables between patients with and without headaches at follow-up. CONCLUSION: In this study, data was found that support that headaches in patients with UIAs improve after treatment and that such improvement is probably unrelated to the size and shape of the UIAs.
- 1 January 2023
- Published by Turkish Neurosurgical Society in Turkish Neurosurgery
- Vol. 34 (4) , 695-700
Effect of size and location of unruptured intracranial aneurysms on self-reported headache
AIM: To describe the relationship between aneurysm size and location with the prevalence of headache at diagnosis and three- and six-month follow-up in a sample of patients with UIA. MATERIAL and METHODS: In this cohort study, patients were diagnosed with UIAs by digital subtraction angiography (DSA). Follow-up visits occurred three and six months after the diagnosis. Headache presence was registered, and headache was further classified by phenotypes. After DSA, the recorded variables were aneurysm number, morphology, location, and size (diameter [W], neck [N], and dome-neck distance [H]). The aspect ratio (H/N) and the dome/neck ratio (W/N) were calculated. The outcome of this study was the self-reported headache status at follow-up. RESULTS: Data from 42 patients and 46 aneurysms were available; 81.0% of patients were women, with a mean age of 57.4 +/- 14.3 years. Headache was reported by 61.9% of the patients. The pain phenotype was tension-type in 38.1%, migraine in 11.9%, neuralgia in 2.4%, and unclassifiable in 9.5%. The median (min-max) measurements were W=5.05 (0.89-22.9); N=3.02 (0.52-17.9); H=5.08 (0.92-23.0); aspect ratio 1.59 (0.68-17.69) and W/N ratio 1.65 (0.62-16.92). Thirty-three patients (37 aneurysms) received treatment, 47.8% by surgical clipping and 32.6% by endovascular occlusion. In the treated patients, headaches had persisted in 14.3% until the first visit and in 9.5% until the second visit. There were no differences in any registered variables between patients with and without headaches at follow-up. CONCLUSION: In this study, data was found that support that headaches in patients with UIAs improve after treatment and that such improvement is probably unrelated to the size and shape of the UIAs.
- 1 August 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (8) , 2109-2114
Survival After Ischemic and Hemorrhagic Stroke: A 4-Year Follow-Up at a Mexican Hospital
- 1 August 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (8) , 2109-2114
Survival After Ischemic and Hemorrhagic Stroke: A 4-Year Follow-Up at a Mexican Hospital
- Open Access
- 1 June 2018
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 76 (6) , 426
Opisthotonus (arc de cercle) in anti-NMDAR encephalitis
A 21-year-old man presented with focal-onset seizures with evolution to bilateral tonic-clonic seizures, fever, and encephalopathy. In our hospital, he was diagnosed with anti-NMDAR encephalitis; this antibody was found to be positive in both serum and cerebrospinal fluid (CBA, IIFT, EUROIMMUN AG, Luebeck, Germany). Other causes of encephalitis were rationally excluded. During his hospital stay, he developed symptoms and signs compatible with catatonia. He was treated with high-dose methylprednisolone pulse therapy and therapeutic plasma exchange. Although he comparatively improved, days after finishing his fifth session of therapeutic plasma exchange, he developed a brief episode of opisthotonus (arc de cercle) (Figure), which resolved without any treatment. He had never had similar episodes in the past. This movement disorder is infrequently seen in contemporary clinical practice. In the 19th century, hysteria was one of the major differential diagnoses of episodic opisthotonus.
- 1 June 2018
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 76 (6) , 426
Open AccessOpisthotonus (arc de cercle) in anti-NMDAR encephalitis
A 21-year-old man presented with focal-onset seizures with evolution to bilateral tonic-clonic seizures, fever, and encephalopathy. In our hospital, he was diagnosed with anti-NMDAR encephalitis; this antibody was found to be positive in both serum and cerebrospinal fluid (CBA, IIFT, EUROIMMUN AG, Luebeck, Germany). Other causes of encephalitis were rationally excluded. During his hospital stay, he developed symptoms and signs compatible with catatonia. He was treated with high-dose methylprednisolone pulse therapy and therapeutic plasma exchange. Although he comparatively improved, days after finishing his fifth session of therapeutic plasma exchange, he developed a brief episode of opisthotonus (arc de cercle) (Figure), which resolved without any treatment. He had never had similar episodes in the past. This movement disorder is infrequently seen in contemporary clinical practice. In the 19th century, hysteria was one of the major differential diagnoses of episodic opisthotonus.
- Open Access
- 31 May 2018
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 388
WhatsApp in Stroke Systems: Current Use and Regulatory Concerns
Smartphone use is extremely common. Applications such as WhatsApp have billions of users and physicians are no exception. Stroke Medicine is a field where instant communication among fairly large groups is essential. In developing countries, economic limitations preclude the possibility of acquiring proper communication platforms. Thus, WhatsApp has been used as an organizational tool, for sharing clinical data, and for real time guidance of clinical care decisions. It has evolved into a cheap, accessible tool for telemedicine. Nevertheless, regulatory and privacy issues must be addressed. Some countries have implemented legislation to address this issue, while others lag behind. In this article, we present an overview on the different roles WhatsApp has acquired as a clinical tool in stroke systems and the potential privacy concerns of its use.
- 31 May 2018
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 388
Open AccessWhatsApp in Stroke Systems: Current Use and Regulatory Concerns
Smartphone use is extremely common. Applications such as WhatsApp have billions of users and physicians are no exception. Stroke Medicine is a field where instant communication among fairly large groups is essential. In developing countries, economic limitations preclude the possibility of acquiring proper communication platforms. Thus, WhatsApp has been used as an organizational tool, for sharing clinical data, and for real time guidance of clinical care decisions. It has evolved into a cheap, accessible tool for telemedicine. Nevertheless, regulatory and privacy issues must be addressed. Some countries have implemented legislation to address this issue, while others lag behind. In this article, we present an overview on the different roles WhatsApp has acquired as a clinical tool in stroke systems and the potential privacy concerns of its use.
- Open Access
- 22 December 2017
- Published by Elsevier in eNeurologicalSci
- Vol. 10, 1-4
Exquisite response to intravenous immunoglobulin in Susac syndrome during pregnancy
- 22 December 2017
- Published by Elsevier in eNeurologicalSci
- Vol. 10, 1-4
Open AccessExquisite response to intravenous immunoglobulin in Susac syndrome during pregnancy
- 21 February 2017
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 26 (4) , 725-732
Temporal Trends in Mortality from Ischemic and Hemorrhagic Stroke in Mexico, 1980-2012
- 21 February 2017
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 26 (4) , 725-732
Temporal Trends in Mortality from Ischemic and Hemorrhagic Stroke in Mexico, 1980-2012
- 1 October 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 357, e196
Stroke in México: mortality trends 1980-2012
- 1 October 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 357, e196
Stroke in México: mortality trends 1980-2012
- 23 March 2015
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (3) , 247-251
Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy
Background and purpose Few studies have investigated the rates of recanalisation after cerebral venous thrombosis (CVT). Our objective was to investigate the recanalisation rate and to identify predictors of recanalisation in patients with CVT. Methods We included 102 patients with confirmed first-ever, non-septic CVT. All patients received anticoagulation for 12 months or until complete recanalisation. To assess recanalisation, patients underwent MR venography every 3 months until partial or complete recanalisation or for 12 months after diagnosis. We conducted two parallel analyses of complete recanalisation versus partial and no recanalisation versus any recanalisation. As a secondary objective we explored the influence of recanalisation on outcome and recurrent events. We calculated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysis using a Cox model. Results The mean age of patients was 33.5±11 years (80 (78.4%) women). Survival analysis indicated that 50% of the patients had any recanalisation (grades I, II and III) by 64 days and complete recanalisation (grade III) by 169 days. Adjusted Cox proportional model revealed that age Conclusions We found that recanalisation occurs over time, until month 11. Complete recanalisation may influence functional outcome.
- 23 March 2015
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (3) , 247-251
Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy
Background and purpose Few studies have investigated the rates of recanalisation after cerebral venous thrombosis (CVT). Our objective was to investigate the recanalisation rate and to identify predictors of recanalisation in patients with CVT. Methods We included 102 patients with confirmed first-ever, non-septic CVT. All patients received anticoagulation for 12 months or until complete recanalisation. To assess recanalisation, patients underwent MR venography every 3 months until partial or complete recanalisation or for 12 months after diagnosis. We conducted two parallel analyses of complete recanalisation versus partial and no recanalisation versus any recanalisation. As a secondary objective we explored the influence of recanalisation on outcome and recurrent events. We calculated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysis using a Cox model. Results The mean age of patients was 33.5±11 years (80 (78.4%) women). Survival analysis indicated that 50% of the patients had any recanalisation (grades I, II and III) by 64 days and complete recanalisation (grade III) by 169 days. Adjusted Cox proportional model revealed that age Conclusions We found that recanalisation occurs over time, until month 11. Complete recanalisation may influence functional outcome.